A new safety layer aims to help robots sense people in real time without slowing production
Updated
February 13, 2026 10:44 AM

An industrial robot in a factory. PHOTO: UNSPLASH
Algorized has raised US$13 million in a Series A round to advance its AI-powered safety and sensing technology for factories and warehouses. The California- and Switzerland-based robotics startup says the funding will help expand a system designed to transform how robots interact with people. The round was led by Run Ventures, with participation from the Amazon Industrial Innovation Fund and Acrobator Ventures, alongside continued backing from existing investors.
At its core, Algorized is building what it calls an intelligence layer for “physical AI” — industrial robots and autonomous machines that function in real-world settings such as factories and warehouses. While generative AI has transformed software and digital workflows, bringing AI into physical environments presents a different challenge. In these settings, machines must not only complete tasks efficiently but also move safely around human workers.
This is where a clear gap exists. Today, most industrial robots rely on camera-based monitoring systems or predefined safety zones. For instance, when a worker steps into a marked area near a robotic arm, the system is programmed to slow down or stop the machine completely. This approach reduces the risk of accidents. However, it also means production lines can pause frequently, even when there is no immediate danger. In high-speed manufacturing environments, those repeated slowdowns can add up to significant productivity losses.
Algorized’s technology is designed to reduce that trade-off between safety and efficiency. Instead of relying solely on cameras, the company utilizes wireless signals — including Ultra-Wideband (UWB), mmWave, and Wi-Fi — to detect movement and human presence. By analysing small changes in these radio signals, the system can detect motion and breathing patterns in a space. This helps machines determine where people are and how they are moving, even in conditions where cameras may struggle, such as poor lighting, dust or visual obstruction.
Importantly, this data is processed locally at the facility itself — not sent to a remote cloud server for analysis. In practical terms, this means decisions are made on-site, within milliseconds. Reducing this delay, or latency, allows robots to adjust their movements immediately instead of defaulting to a full stop. The aim is to create machines that can respond smoothly and continuously, rather than reacting in a binary stop-or-go manner.
With the new funding, Algorized plans to scale commercial deployments of its platform, known as the Predictive Safety Engine. The company will also invest in refining its intent-recognition models, which are designed to anticipate how humans are likely to move within a workspace. In parallel, it intends to expand its engineering and support teams across Europe and the United States. These efforts build on earlier public demonstrations and ongoing collaborations with manufacturing partners, particularly in the automotive and industrial sectors.
For investors, the appeal goes beyond safety compliance. As factories become more automated, even small improvements in uptime and workflow continuity can translate into meaningful financial gains. Because Algorized’s system works with existing wireless infrastructure, manufacturers may be able to upgrade machine awareness without overhauling their entire hardware setup.
More broadly, the company is addressing a structural limitation in industrial automation. Robotics has advanced rapidly in precision and power, yet human-robot collaboration is still governed by rigid safety systems that prioritise stopping over adapting. By combining wireless sensing with edge-based AI models, Algorized is attempting to give machines a more continuous awareness of their surroundings from the start.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM

Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.